Tracking a promising cancer Drug's Real-World impact
NCT ID NCT07269249
Summary
This study is observing how well the immunotherapy drug dostarlimab works for patients with a specific type of advanced rectal cancer in real-world medical settings, not a controlled trial. It will follow about 50 patients in Italy who are already receiving this treatment to see how their tumors respond, how long the benefits last, and what side effects occur. The goal is to gather practical evidence on the drug's effectiveness and safety outside of initial research studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica
NOT_YET_RECRUITINGNaples, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale
RECRUITINGNaples, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.